Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ekstern digital fysiologisk datainnsamling i kreft: En MSK-registerprotokoll

28. september 2026 oppdatert av: Memorial Sloan Kettering Cancer Center

Remote Digital Physiological Data Collection in Cancer: An MSK Registry Protocol

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Project 1: HealthKit This prospective registry cohort study will aim to recruit a total of 3,000 patients and 500 adults without a history of cancer. The targeted patient cohorts / settings will aim to be : (1) pre-treatment / during treatment: patients with newly diagnosed early-stage, low-grade, or locally advanced solid tumors that are either pre- or during treatment, (2) post-treatment: patients with primary solid tumor diagnose is that are post-treatment, (3) advanced disease setting: patients diagnosed with metastatic or high-grade disease, (4) patients enrolled onto investigational trials in the early drug development (EDD) Service, (5) patients admitted to Urgent Care Center (UCC), and (6) patients completing a Survivorship Patient Self-Assessment as part of follow-up in an MSK Survivorship clinic. This study will accrue patients receiving care at any MSK site. Adults without a history of cancer will be recruited as a comparison group. The targeted adults without a history of cancer cohorts will aim to be (n=250/cohort): (7) adults without a history of cancer <50 years of age, and (8) adults without a history of cancer aged greater than or equal to 50 years.

Project 2: DigIT-Ex This prospective registry cohort study will aim to recruit a total of 168 patients and 24 adults without a history of cancer. The targeted adult patient cohorts / settings will be (n=12/cohort), excluding cohort 6, and 10 which will be (n=48): (1) patients scheduled to undergo bone marrow transplantation, (2) patients newly diagnosed with acute myeloid leukemia (AML), (3) patients scheduled to undergo surgery for localized prostate cancer (4) patients scheduled to undergo surgery for lung cancer, (5) patients scheduled to undergo total neoadjuvant therapy for advanced rectal cancer, (6) patients scheduled to undergo antiandrogen therapy for advanced prostate cancer, and (7) patients scheduled to undergo chemotherapy for metastatic pancreatic cancer. and (10) patients scheduled to undergo surgery for metastatic bone disease.

For Cohort 10 (patients scheduled to undergo surgery for metastatic bone disease), an expanded DigIT-Ex sub-study will be conducted. This sub-study will enroll up to 40 patients with metastatic cancer to bone of the lower extremity who are undergoing non-emergent orthopaedic stabilization surgery. Participants will be monitored longitudinally for functional activity using wearable activity monitors for a minimum of 5 days prior to surgery and for up to 4 months following surger The targeted adults without a history of cancer cohorts will be (n=12/cohort): (8) individuals without a history of cancer aged less than 50 years, and (9) individuals without a history of cancer aged greater than or equal to 50 years.

Studietype

Observasjonsmessig

Registrering (Antatt)

3692

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Jessica Scott, PhD
  • Telefonnummer: 646-888-8093

Studer Kontakt Backup

Studiesteder

  • Forente stater
    • New York
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Ta kontakt med:
          • Jessica Scott, PhD
          • Telefonnummer: 646-888-8093
        • Ta kontakt med:
          • Luke Pike, MD, DPhil
          • Telefonnummer: 212-639-8157
        • Hovedetterforsker:
          • Luke Pike, MD, DPhil

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Potential participants will be identified by a member of the patient's care team, a protocol investigator, or research staff at Memorial Sloan Kettering Cancer Center (MSK).

Beskrivelse

Inclusion Criteria:

Project 1: HealthKit

  • Individuals who meet at least one of the following criteria:

    • Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
    • Historical diagnosis of primary invasive solid tumor
    • Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
    • Enrolled onto an investigational trial in the EDD Service
    • Seen in the MSK UCC from 2021 and onwards
    • Completion of Survivorship Patient Self-Assessment
    • Adult without a history of cancer <50 years of age
    • Adult without a history of cancer ≥ 50 years of age

  • ≥18 years old

  • Own an Apple iPhone or Android with valid operating software

  • Self-reported "very well" comprehension of written and verbal English language

  • Willing and able to provide informed consent and HIPAA authorization for the release of personal health information

Project 2: DigIT-Ex

Individuals who meet one of the following criteria:

  • Patients at MSK who are:

  • Scheduled to undergo any type of BMT (Cohort 1)

  • Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)

  • Scheduled to undergo any surgery for prostate cancer (Cohort 3)

  • Scheduled to undergo any lung cancer surgery (Cohort 4)

  • Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)

  • Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):

  • High risk/very high localized, locally advanced,

  • Biochemically recurrent prostate cancer

  • Treatment naïve, low-volume metastatic prostate cancer

  • Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)

  • Receiving outpatient care at Memorial Sloan Kettering Cancer Center (MSK)(Cohort 10)

  • Diagnosed with metastatic cancer to bone For purposes of this study, metastatic bone disease includes skeletal involvement from multiple myeloma (Cohort 10)

  • Scheduled for non-emergent orthopaedic surgery to stabilize lower-extremity bone metastases (Cohort 10)

  • Able to undergo at least 5 consecutive days of preoperative monitoring prior to surgery (Cohort 10)

  • Have had a CT scan including the L3 vertebral level within 3 months before surgery (used to assess skeletal muscle mass and sarcopenia) (Cohort 10)

  • Have a ≥50% predicted likelihood of 3-month postoperative survival, as estimated by the PATHFx clinical decision-support tool (Cohort 10

  • Individuals without cancer <50 years of age (Cohort 8)

  • Individuals without cancer ≥50 years of age (Cohort 9)

    • 18 to 90 years old at the time of consent
    • Willing and able to download the Withings Health Mate app onto their personal mobile device
    • Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent for Cohorts 1-9, and 4 months following consent for Cohort 10.
    • Willing to provide informed consent

Exclusion Criteria:

Project 1: HealthKit

  • Unable or unwilling to successfully export and /or share physiological data

Project 2: DigIT-Ex

  • Unable or unwilling to appropriately use digital platforms or devices
  • Require a wheelchair for ambulation (Cohort 10)
  • Are undergoing stabilization surgery for a primary bone tumor (rather than metastatic disease) (Cohort 10)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
establish a mechanism within the institution to prospectively collect / extract digital remote physiological data among patients with cancer
Tidsramme: 1 year

to create a repository and infrastructure to address novel questions of clinical importance.
1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Memorial Sloan Kettering Cancer Center

Etterforskere

  • Hovedetterforsker: Luke Pike, MD, DPhil, Memorial Sloan Kettering Cancer Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. mai 2022

Primær fullføring (Antatt)

1. juli 2027

Studiet fullført (Antatt)

1. juli 2027

Datoer for studieregistrering

Først innsendt

20. mai 2022

Først innsendt som oppfylte QC-kriteriene

20. mai 2022

Først lagt ut (Faktiske)

25. mai 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • 20-330

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere